Identifying biomarkers for prostate cancer patients on active surveillance
Prognostic Radiomic Signatures in Prostate Cancer Patients on Active Surveillance
['FUNDING_OTHER'] · WASHINGTON UNIVERSITY · NIH-10927436
This study is looking at new ways to use imaging and molecular tests to find markers that help doctors decide if men with prostate cancer can safely watch their condition instead of starting treatment right away, making it easier and safer for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10927436 on ClinicalTrials.gov |
What this research studies
This research investigates the use of advanced imaging and molecular techniques to identify biomarkers that can help determine which prostate cancer patients are suitable for active surveillance. By analyzing the interactions between cancer cells and the surrounding extracellular matrix, the study aims to improve the accuracy of monitoring disease progression. Patients will be monitored over time to ensure timely treatment if necessary, reducing the risks associated with immediate invasive procedures. The research utilizes non-invasive methods like MRI and molecular tests to enhance patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with very low, low, or favorable intermediate-risk prostate cancer who are considering active surveillance as a treatment option.
Not a fit: Patients with high-risk prostate cancer or those who have already undergone definitive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate monitoring and treatment decisions for prostate cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using biomarkers and imaging techniques for cancer prognosis, suggesting that this approach could yield significant advancements in prostate cancer management.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LUNA CASTANEDA, JOSE MARCIO — WASHINGTON UNIVERSITY
- Study coordinator: LUNA CASTANEDA, JOSE MARCIO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancer Prognosis, Cancers